# Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia

> **NCT00640601** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 331 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Quetiapine Fumarate Extended- Release

## Key facts

- **NCT ID:** NCT00640601
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2012-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640601, "Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00640601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*